Today's News |
First AI enabled ROI Radiation Reduction shutter technology FluoroShield™ cleared by FDA
Thursday, April 18, 2019Company Profile | Follow Company
Vancouver, BC, April 18, 2019--(T-Net)--Omega Medical Imaging announced this month the launch of FluoroShield™ in conjunction with technology partner IKOMED Technologies, Vancouver, BC Canada.
FluoroShield™ is an Artificial Intelligence powered Region of Interest (ROI) Radiation exposure reduction solution for interventional X-ray imaging available only on Omega's Flat Panel detector CS-series product lines.
FluoroShield™ combines the power of AI, an ultra-fast collimator and the worlds most advanced image processing to deliver a Region of Interest solution that has shown to reduce radiation exposure up to ~84%, seamlessly helping Interventional clinicians better reach their ALARA goals.
Omega Medical Imaging LLC based in Sanford Florida USA is an innovator in the design, manufacture, delivery, and support of Interventional X-Ray Imaging devices for hospitals and healthcare facilities around the globe.
IKOMED Technologies Inc, Vancouver, BC Canada is a medical device company developing novel medical solutions based on proprietary technology.
----------------------------------
Editor's Note: Ikomed is chaired by Amos Michelson (who was past president of heavyweight BC tech company CREO Products (acquired by Kodak). Mr. Michelson was the CEO of Creo, leading it from 1995 till its acquisition by Kodak in 2005 for $1 Billion USD. Prior to Creo, Mr. Michelson was the CEO of Opal Inc. and the COO of Optrotech Ltd.
Ikomed is co-founded by Dan Gelbart. Mr. Gelbart also co-founded Creo Inc. in 1984 and served as President and then CTO until July, 2005
----------------------------------
About Ikomed
IKOMED Technologies Inc. is developing novel medical devices based on proprietary technology .
Our X Ray radiation reduction technology is delivering breakthrough solutions for reducing the exposure to ionizing radiation for millions of patients undergoing minimally invasive medical procedures each year and the medical staff involved in these procedures.
Decreased radiation exposure during minimally invasive procedures maintains the health of patients and medical staff. In turn, IKOMED's technology supports the development of more complex and lengthy fluoroscopy-guided minimally invasive procedures that otherwise would result in extremely high doses of radiation. As governmental agencies call for more careful consideration of medical imaging radiation, IKOMED's technology is being developed to respond to this particular need.
We are also developing a non-invasive treatment for COPD.